StocksDeepDive
Blog
Research notes and valuation walk-throughs - the reasoning behind the numbers the site computes, written out in full.
RMD: My Valuation of ResMed and Why I Stopped My Research
After analysing most of ResMed's (RMD) business, I came across three major headwinds: 1 GLP‑1 drugs 2 Philips recovery 3 Regulatory and Medicare related…
Run the numbers yourself
Every figure discussed here comes from the same engine you can point at any ticker — Stock Deep Dive, side-by-side Comparison or the Stock Scanner.